Cargando…
CAR-T Cell Therapy in Large B Cell Lymphoma
Large B-cell lymphomas (LBCLs) are among the most frequent (about 30%) non-Hodgkin’s lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients can be cured with first-line chemoimmunotherapy using the R-CHOP regimen. Patients with refractory or relapsing disease show a...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Università Cattolica del Sacro Cuore
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631715/ https://www.ncbi.nlm.nih.gov/pubmed/38028399 http://dx.doi.org/10.4084/MJHID.2023.066 |